Through western blotting, our findings showed a significant reduction in the expression of Aβ1–42 and BACE-1 in the brains of Aβ1–42 + Luteolin-treated mice, compared to those of Aβ1–42-induced AD mice. This evidence concerns the gene BACE1 and Alzheimer disease.